Figure 2.

MALT1-independent inhibition of osteoclast-specific gene induction by mepazine. BMCs isolated from Malt1 wild-type (WT) and Malt1 knock-out (KO) mice were differentiated into osteoclasts by treatment with M-CSF (20 ng/mL), as well as RANKL (50 ng/mL) in the presence or absence of mepazine (MEPA, 13 µM) every two days. Samples without mepazine were treated with an equal volume (0.1% final concentration) DMSO as solvent control. The / symbol represents that no RANKL or mepazine was added. mRNA was extracted at day 9 and qPCR was performed for (a) TRAP, (b) CTSK (Cathepsin K) and (c) CALCR (Calcitonin receptor). Values are the mean of technical triplicates ± S.D. Data are representative of two independent experiments. Statistical differences were determined by Student’s t-test, ** represents p ≤ 0.01 and *** represents p ≤ 0.001.